319 related articles for article (PubMed ID: 23700415)
1. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
2. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
3. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Körner M; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B
J Allergy Clin Immunol; 2009 Nov; 124(5):1047-54. PubMed ID: 19895993
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).
Ruëff F; Bauer A; Becker S; Brehler R; Brockow K; Chaker AM; Darsow U; Fischer J; Fuchs T; Gerstlauer M; Gernert S; Hamelmann E; Hötzenecker W; Klimek L; Lange L; Merk H; Mülleneisen NK; Neustädter I; Pfützner W; Sieber W; Sitter H; Skudlik C; Treudler R; Wedi B; Wöhrl S; Worm M; Jakob T
Allergol Select; 2023; 7():154-190. PubMed ID: 37854067
[TBL] [Abstract][Full Text] [Related]
6. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
7. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
8. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
9. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines.
Fiedler C; Miehe U; Treudler R; Kiess W; Prenzel F
Int Arch Allergy Immunol; 2017; 172(3):167-172. PubMed ID: 28380475
[TBL] [Abstract][Full Text] [Related]
11. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
12. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
14. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Haeberli G; Brönnimann M; Hunziker T; Müller U
Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
[TBL] [Abstract][Full Text] [Related]
15. [Therapy control of specific hymenoptera venom allergy].
Aust W; Wichmann G; Dietz A
Laryngorhinootologie; 2010 Dec; 89(12):725-8. PubMed ID: 21132618
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
17. [Sting challenge: indications and execution].
Ruëff F; Przybilla B
Hautarzt; 2014 Sep; 65(9):796-801. PubMed ID: 25234628
[TBL] [Abstract][Full Text] [Related]
18. Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?
Sahiner UM; Durham SR
Front Immunol; 2019; 10():1959. PubMed ID: 31497015
[TBL] [Abstract][Full Text] [Related]
19. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
20. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings.
Ewan PW; Deighton J; Wilson AB; Lachmann PJ
Clin Exp Allergy; 1993 Aug; 23(8):647-60. PubMed ID: 8221268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
